好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Case of Anti-NMDA Receptor Encephalitis Presenting in a Toddler with Hemorrhagic Cavernomas
Autoimmune Neurology
P2 - Poster Session 2 (9:00 AM-3:00 PM)
044

N/A
N/A
Introduction: Anti-N-methyl-D-aspartate (anti-NMDA) receptor encephalitis signifies an autoimmune antibody-mediated neuropsychiatric disease that often presents with a set of well-described clinical characteristics and other times manifests with more rare features. The heterogeneity of patient presentation can propose a diagnostic challenge to even the best clinical neurologist. Anti-NMDA receptor encephalitis should be considered for patients who possess an alternative existing diagnosis that shows atypical progression because early recognition and treatment of the disease can help reduce long-term complications.
Case Report: We illustrate a 14 month-old previously healthy boy with anti-NMDA receptor encephalitis who first presented with focal seizures. Initial neurologic imaging revealed intracranial hemorrhage with underlying cavernous malformations. He responded well to a single anti-seizure agent, but re-presented one week later with transient weakness that was ultimately attributed to worsening intracranial hemorrhage with surrounding edema. Upon his third presentation, he developed dyskinesias, sleep dysfunction, autonomic instability, cognitive changes, and motor regression, prompting further work-up with lumbar puncture. Cerebrospinal fluid analysis showed a positive NMDA antibody titer of 1:40. Treatment with intravenous steroids, plasma exchange (PLEX), and intravenous immune globulin (IVIg), followed by infusions of Rituximab and Cyclophosphamide resulted in gradual, marked clinical improvement.
Conclusion: This case study and literature review explores the relationship between cavernous malformations, intracranial hemorrhage, and anti-NMDA receptor encephalitis, and how these diagnoses respond to escalating immunomodulation therapies. Consideration of this entity should be made when the neurologic examination does not follow an expected course of a previously established diagnosis. With timely recognition and aggressive treatment approaches, patients can achieve substantial clinical improvement.
Authors/Disclosures
Kayla Jacques, MD
PRESENTER 		Dr. Jacques has nothing to disclose.
Lydia Marcus, MD (University of Alabama Medical Center, Child Neurology) Dr. Marcus has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Ragsdale LLC. The institution of Dr. Marcus has received research support from NIAID.